Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
Saved in:
| Published in: | Biologics: Targets & Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1864030191121072134 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Biologics: Targets & Therapy |
| description | |
| discipline_display | Natural Sciences |
| discipline_facet | Natural Sciences |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:18856 |
| institution | FRELIP |
| journal_source_facet | Biologics: Targets & Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison Biology Natural Sciences — Life Sciences Natural Sciences |
| sub_discipline_display | Natural Sciences — Life Sciences |
| sub_discipline_facet | Natural Sciences — Life Sciences |
| subject_display | Biology Natural Sciences — Life Sciences Natural Sciences Biology Natural Sciences — Life Sciences Natural Sciences |
| subject_facet | Biology Natural Sciences — Life Sciences Natural Sciences |
| title | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_auth | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_full | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_fullStr | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_full_unstemmed | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_short | First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison |
| title_sort | first-line serplulimab versus other anti-pd-1/pd-l1 antibodies plus chemotherapy for esophageal squamous cell carcinoma: a systematic review with benefit-risk assessment via matching-adjusted indirect comparison |
| topic | Biology Natural Sciences — Life Sciences Natural Sciences |
| url | https://www.dovepress.com/first-line-serplulimab-versus-other-anti-pd-1pd-l1-antibodies-plus-che-peer-reviewed-fulltext-article-BTT |